Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Starlight 2: Fezolinetant for Vasomotor Symptoms in Japanese Menopausal Women
jRCT2031230571Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fezolinetant in menopause (3 arms), sponsored by Astellas Pharma. Primary endpoint: Mean change in frequency of mild to severe vasomotor symptoms from baseline to week 8. Started Feb 2024; status: completed.
02
Drugs
fezolinetant
03
Conditions
menopause
Beyond the preview
Go deeper on jRCT2031230571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230571.